BNP PARIBAS ASSET MANAGEMENT Holding S.A. Grows Stock Position in Illumina, Inc. $ILMN

Key Points

• BNP Paribas Asset Management Holding S.A. has increased its stake in Illumina, Inc. by 8.5%, now owning 75,135 shares valued at approximately $5.96 million.
• Illumina reported a 12-month low of $68.70 and a high of $156.66, with a current market cap of $15.45 billion and a PE ratio of 12.73.
• While analysts have mixed reviews, the consensus rating for Illumina's stock is "Hold", with a price target of $124.58.

BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its holdings in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 8.5% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 75,135 shares of the life sciences company's stock after acquiring an additional 5,902 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A.'s holdings in Illumina were worth $5,961,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of ILMN. Freedom Investment Management Inc. grew its position in shares of Illumina by 3.7% in the fourth quarter. Freedom Investment Management Inc. now owns 2,856 shares of the life sciences company's stock valued at $382,000 after purchasing an additional 101 shares in the last quarter. Moors & Cabot Inc. boosted its stake in Illumina by 2.5% during the first quarter. Moors & Cabot Inc. now owns 5,855 shares of the life sciences company's stock worth $465,000 after buying an additional 145 shares during the last quarter. Tokio Marine Asset Management Co. Ltd. grew its holdings in Illumina by 3.0% in the 1st quarter. Tokio Marine Asset Management Co. Ltd. now owns 5,604 shares of the life sciences company's stock valued at $445,000 after buying an additional 164 shares in the last quarter. Probity Advisors Inc. increased its stake in shares of Illumina by 12.2% in the 4th quarter. Probity Advisors Inc. now owns 2,054 shares of the life sciences company's stock worth $274,000 after acquiring an additional 224 shares during the last quarter. Finally, Xponance Inc. increased its stake in shares of Illumina by 1.0% in the 1st quarter. Xponance Inc. now owns 26,762 shares of the life sciences company's stock worth $2,123,000 after acquiring an additional 264 shares during the last quarter. 89.42% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

ILMN has been the subject of a number of analyst reports. Royal Bank Of Canada upped their price objective on shares of Illumina from $118.00 to $126.00 and gave the company an "outperform" rating in a report on Friday, August 1st. Piper Sandler decreased their target price on shares of Illumina from $190.00 to $185.00 and set an "overweight" rating on the stock in a report on Thursday, May 15th. Guggenheim cut their price target on shares of Illumina from $122.00 to $114.00 and set a "buy" rating for the company in a report on Friday, May 9th. Morgan Stanley lifted their price target on shares of Illumina from $100.00 to $105.00 and gave the company an "equal weight" rating in a research report on Monday, August 4th. Finally, Evercore ISI increased their price objective on Illumina from $116.00 to $128.00 and gave the stock an "outperform" rating in a research report on Tuesday, July 8th. Seven research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have issued a Sell rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus price target of $124.58.

Illumina Trading Up 2.5%

Shares of ILMN traded up $2.51 during midday trading on Friday, hitting $101.80. 1,964,101 shares of the stock were exchanged, compared to its average volume of 1,883,205. Illumina, Inc. has a 52-week low of $68.70 and a 52-week high of $156.66. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.41 and a current ratio of 1.81. The stock has a fifty day simple moving average of $98.18 and a 200 day simple moving average of $89.13. The firm has a market cap of $15.65 billion, a P/E ratio of 12.89, a P/E/G ratio of 2.23 and a beta of 1.37.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its earnings results on Thursday, July 31st. The life sciences company reported $1.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.17. Illumina had a return on equity of 28.93% and a net margin of 29.36%.The firm had revenue of $1.06 billion for the quarter, compared to analyst estimates of $1.12 billion. During the same quarter in the prior year, the company earned $0.36 EPS. Illumina's revenue was down 4.8% on a year-over-year basis. Illumina has set its FY 2025 guidance at 4.450-4.55 EPS. On average, research analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.